Department of Neuroscience, University of Rome Tor Vergata, 1 Montpellier Street-00133-Rome, Italy.
CNS Neurol Disord Drug Targets. 2013 Jun;12(4):507-11. doi: 10.2174/1871527311312040010.
Alzheimer's disease (AD) is strictly connected with aging and frailty. Although dementia contributes to frailty, it is not well established whether AD patients could be per se defined "frail". At the same time, it is not known whether among AD patients, which are a heterogeneous group of patients, it is possible to identify a subgroup of frail individuals. In this work we sought indices useful to identify "the frail AD". To do this we evaluated disease progression rate and response to pharmacological treatment (Mini Mental State Examination evaluation), cerebrospinal fluid biomarkers (amyloid-β.42, total-tau and phospho-tau) levels, inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) in a group of patients with a diagnosis of probable AD. Our results describe the clinical profile of patients which could be considered as non-responders and rapidly progressive AD. In the absence of other indices we conclude that patients with these features could well be considered "frail" among AD.
阿尔茨海默病(AD)与衰老和虚弱密切相关。尽管痴呆症会导致虚弱,但 AD 患者是否可以被定义为“虚弱”尚不清楚。同时,也不知道在 AD 患者这一异质性群体中,是否有可能确定一个虚弱个体亚组。在这项工作中,我们寻求有用的指标来识别“虚弱的 AD”。为此,我们评估了疾病进展速度和对药物治疗的反应(Mini Mental State Examination 评估)、脑脊液生物标志物(淀粉样蛋白-β.42、总 tau 和磷酸化 tau)水平、炎症指标(血清 C 反应蛋白、纤维蛋白原、D-二聚体)在一组被诊断为可能的 AD 的患者中。我们的结果描述了可以被认为是无反应者和快速进展性 AD 的患者的临床特征。在没有其他指标的情况下,我们得出结论,具有这些特征的患者在 AD 中可以被很好地视为“虚弱”。